WASHINGTON, DC and MONTREAL, QUEBEC--(CCNMatthews - Nov. 13, 2006) - Today at the 70th Annual Meeting of the American College of Rheumatology, IBEX Technologies Inc. (TSX:IBT), an innovator in the development of diagnostics for the management of arthritis and cancer, announced the results of two clinical studies involving the company’s C2C biomarker assay. C2C is a biomarker of cartilage degradation and re-modeling, a normal process that is found in children and adults with osteoarthritis (OA) and rheumatoid arthritis (RA). The C2C assay currently sold measures the amount of real-time collagen degradation in serum, which allows researchers to monitor the progression of OA and RA. Based on encouraging preliminary results, IBEX plans to launch a urine-based C2C assay at the end of 2006.
